Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 397 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
LEXIVA (GW433908), Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more
Conditions
Intervertebral Disc Degeneration, Osteoarthritis, Spine
Interventions
EOS imaging
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Prostate Cancer
Interventions
PSMA ADC
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Conditions
Endograft Implantation to Repair Abdominal Aortic Aneurysm
Interventions
Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional

AI ENRICH - AI Detection of ICH

NCT03865979
Conditions
Intracerebral Hemorrhage
Interventions
Viz RECRUIT
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Little Rock, Arkansas • Evanston, Illinois • Camden, New Jersey + 3 more
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness of Three Lucid Dreaming and Sleep Hygiene Techniques

NCT03913988
Conditions
Anxiety
Interventions
Lucid Dream, Stress Reduction, Sleep Hygiene Techniques
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Tracheal Intubation Coaching in NICUs

NCT03194503
Conditions
Failed or Difficult Intubation, Sequela, Intubation;Difficult, Intubation Complication
Interventions
VL Coaching training using C-MAC video laryngoscope
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
22 Years to 70 Years
Enrollment
1,512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 4 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

NCT01667978
Conditions
Pregnancy, HIV, AIDS
Interventions
Norethindrone acetate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Los Angeles, California
Conditions
Digital Intervention, Bibliotherapy
Interventions
Digital technology, Bibliotherapy
Device · Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Conditions
Patulous Eustachian Tube Dysfunction, Eustachian Tube Dysfunction
Interventions
Internal nasal dilator
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Low Back Pain
Interventions
Hydromorphone ER, Sugar pill
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting No phase listed Observational

Abbott Structural Heart Device Registry

NCT06590467
Conditions
Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions
Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more
Conditions
COVID-19
Interventions
Shionogi Protease Inhibitor (S-217622), placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
103
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-PI
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more
Conditions
Brain Cancer
Interventions
MRI perfusion and PET/CT scans
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Conditions
Graft Versus Host Disease
Interventions
Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
Biological
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
PI, RTV, FTC/TDF, Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more
Conditions
Glioblastoma, Recurrent Glioblastoma, Skin Toxicity
Interventions
Clindamycin Phosphate, Triamcinolone Acetonide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Evanston, Illinois • Boston, Massachusetts • St Louis, Missouri + 4 more
Conditions
HIV-Associated Lipodystrophy Syndrome
Interventions
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Honolulu, Hawaii • Huntersville, North Carolina + 1 more
Conditions
Hypertension, Stroke
Interventions
Informational Guide for Patients, Video-Assisted Coaching, Monograph for Physicians, Educational Coaching, Control
Other · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Lung Cancer
Interventions
Curative Radiotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
Bo Lu
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Columbia, Missouri • New Brunswick, New Jersey • Rochester, New York
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
To Assess the Feasibility, Visualization Capability, and Optimal Dosing of ICG Fluorescence Imaging for Intraoperative Assessment of Knee Tissue Perfusion
Interventions
Intravenous administration of indocyanine green (SPY Agent Green) 2 mL of SPY Agent Green (5.0 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 3 mL of SPY Agent Green (7.5 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 4 mL of SPY Agent Green (10 mg dose), Intravenous administration of indocyanine green (SPY Agent Green)5 mL of SPY Agent Green (12.5 mg dose)
Combination Product
Lead sponsor
Henry Ford Health System
Other
Eligibility
14 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Detroit, Michigan